The sentinel within: Exploiting the immune system for cancer biomarkers

Research output: Contribution to journalArticle

213 Citations (Scopus)

Abstract

The release of proteins from tumors triggers an immune response in cancer patients. These tumor antigens arise from several mechanisms including tumor-specific alterations in protein expression, mutation, folding, degradation, or intracellular localization. Responses to most tumor antigens are rarely observed in healthy individuals, making the response itself a biomarker that betrays the presence of underlying cancer. Antibody immune responses show promise as clinical biomarkers because antibodies have long half-lives in serum, are easy to measure, and are stable in blood samples. However, our understanding of the specificity and the impact of the immune response in early stages of cancer is limited. The immune response to cancer, whether endogenous or driven by vaccines, involves highly specific T lymphocytes (which target tumor-derived peptides bound to self-MHC proteins) and B lymphocytes (which generate antibodies to tumor-derived proteins). T cell target antigens have been identified either by expression cloning from tumor cDNA libraries, or by prediction based on patterns of antigen expression ("reverse immunology"). B cell targets have been similarly identified using the antibodies in patient sera to screen cDNA libraries derived from tumor cell lines. This review focuses on the application of recent advances in proteomics for the identification of tumor antigens. These advances are opening the door for targeted vaccine development, and for using immune response signatures as biomarkers for cancer diagnosis and monitoring.

Original languageEnglish (US)
Pages (from-to)1123-1133
Number of pages11
JournalJournal of Proteome Research
Volume4
Issue number4
DOIs
StatePublished - Jul 2005
Externally publishedYes

Fingerprint

Immune system
Tumor Biomarkers
Tumors
Immune System
Neoplasm Antigens
Neoplasms
T-cells
Antibodies
Biomarkers
Gene Library
Vaccines
Cells
Immunology
Antigens
Proteins
B-Lymphocytes
Lymphocytes
Cloning
Neoplasm Antibodies
T-Lymphocytes

Keywords

  • Antibody
  • Biomarkers
  • Protein array
  • Proteomics
  • Tumor antigen
  • Tumor immunology

ASJC Scopus subject areas

  • Genetics
  • Biotechnology
  • Biochemistry

Cite this

The sentinel within : Exploiting the immune system for cancer biomarkers. / Anderson, Karen; LaBaer, Joshua.

In: Journal of Proteome Research, Vol. 4, No. 4, 07.2005, p. 1123-1133.

Research output: Contribution to journalArticle

@article{5d174004d7ee4c32a8c5f379352e1cf1,
title = "The sentinel within: Exploiting the immune system for cancer biomarkers",
abstract = "The release of proteins from tumors triggers an immune response in cancer patients. These tumor antigens arise from several mechanisms including tumor-specific alterations in protein expression, mutation, folding, degradation, or intracellular localization. Responses to most tumor antigens are rarely observed in healthy individuals, making the response itself a biomarker that betrays the presence of underlying cancer. Antibody immune responses show promise as clinical biomarkers because antibodies have long half-lives in serum, are easy to measure, and are stable in blood samples. However, our understanding of the specificity and the impact of the immune response in early stages of cancer is limited. The immune response to cancer, whether endogenous or driven by vaccines, involves highly specific T lymphocytes (which target tumor-derived peptides bound to self-MHC proteins) and B lymphocytes (which generate antibodies to tumor-derived proteins). T cell target antigens have been identified either by expression cloning from tumor cDNA libraries, or by prediction based on patterns of antigen expression ({"}reverse immunology{"}). B cell targets have been similarly identified using the antibodies in patient sera to screen cDNA libraries derived from tumor cell lines. This review focuses on the application of recent advances in proteomics for the identification of tumor antigens. These advances are opening the door for targeted vaccine development, and for using immune response signatures as biomarkers for cancer diagnosis and monitoring.",
keywords = "Antibody, Biomarkers, Protein array, Proteomics, Tumor antigen, Tumor immunology",
author = "Karen Anderson and Joshua LaBaer",
year = "2005",
month = "7",
doi = "10.1021/pr0500814",
language = "English (US)",
volume = "4",
pages = "1123--1133",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "4",

}

TY - JOUR

T1 - The sentinel within

T2 - Exploiting the immune system for cancer biomarkers

AU - Anderson, Karen

AU - LaBaer, Joshua

PY - 2005/7

Y1 - 2005/7

N2 - The release of proteins from tumors triggers an immune response in cancer patients. These tumor antigens arise from several mechanisms including tumor-specific alterations in protein expression, mutation, folding, degradation, or intracellular localization. Responses to most tumor antigens are rarely observed in healthy individuals, making the response itself a biomarker that betrays the presence of underlying cancer. Antibody immune responses show promise as clinical biomarkers because antibodies have long half-lives in serum, are easy to measure, and are stable in blood samples. However, our understanding of the specificity and the impact of the immune response in early stages of cancer is limited. The immune response to cancer, whether endogenous or driven by vaccines, involves highly specific T lymphocytes (which target tumor-derived peptides bound to self-MHC proteins) and B lymphocytes (which generate antibodies to tumor-derived proteins). T cell target antigens have been identified either by expression cloning from tumor cDNA libraries, or by prediction based on patterns of antigen expression ("reverse immunology"). B cell targets have been similarly identified using the antibodies in patient sera to screen cDNA libraries derived from tumor cell lines. This review focuses on the application of recent advances in proteomics for the identification of tumor antigens. These advances are opening the door for targeted vaccine development, and for using immune response signatures as biomarkers for cancer diagnosis and monitoring.

AB - The release of proteins from tumors triggers an immune response in cancer patients. These tumor antigens arise from several mechanisms including tumor-specific alterations in protein expression, mutation, folding, degradation, or intracellular localization. Responses to most tumor antigens are rarely observed in healthy individuals, making the response itself a biomarker that betrays the presence of underlying cancer. Antibody immune responses show promise as clinical biomarkers because antibodies have long half-lives in serum, are easy to measure, and are stable in blood samples. However, our understanding of the specificity and the impact of the immune response in early stages of cancer is limited. The immune response to cancer, whether endogenous or driven by vaccines, involves highly specific T lymphocytes (which target tumor-derived peptides bound to self-MHC proteins) and B lymphocytes (which generate antibodies to tumor-derived proteins). T cell target antigens have been identified either by expression cloning from tumor cDNA libraries, or by prediction based on patterns of antigen expression ("reverse immunology"). B cell targets have been similarly identified using the antibodies in patient sera to screen cDNA libraries derived from tumor cell lines. This review focuses on the application of recent advances in proteomics for the identification of tumor antigens. These advances are opening the door for targeted vaccine development, and for using immune response signatures as biomarkers for cancer diagnosis and monitoring.

KW - Antibody

KW - Biomarkers

KW - Protein array

KW - Proteomics

KW - Tumor antigen

KW - Tumor immunology

UR - http://www.scopus.com/inward/record.url?scp=23944522808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23944522808&partnerID=8YFLogxK

U2 - 10.1021/pr0500814

DO - 10.1021/pr0500814

M3 - Article

C2 - 16083262

AN - SCOPUS:23944522808

VL - 4

SP - 1123

EP - 1133

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 4

ER -